Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

Last updated: December 12, 2025
Sponsor: Cedars-Sinai Medical Center
Overall Status: Suspended

Phase

N/A

Condition

Adenocarcinoma

Treatment

6D-MRI

Clinical Study ID

NCT04700488
STUDY00000573
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Pancreatic cancer patients (with resectable or borderline resectable or locallyadvanced tumors) who will undergo neoadjuvant chemotherapy

  • Patients able to undergo at least two sets of MRI sessions

Exclusion

Exclusion Criteria:

  • Patients who have previously been treated for PDAC

  • Patients unable to undergo MRI exam w/contrast

  • Patients with metastatic pancreatic cancer visualized on index diagnostic imaging

  • Patients with certain metallic implants

  • Patients experiencing claustrophobia

  • Persons with allergy to animal dander or animal-instigated asthma

Study Design

Total Participants: 36
Treatment Group(s): 1
Primary Treatment: 6D-MRI
Phase:
Study Start date:
May 19, 2022
Estimated Completion Date:
January 31, 2026

Study Description

The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT).

Connect with a study center

  • Cedars-Sinai Medical Center

    Los Angeles 5368361, California 5332921 90048
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.